Eric Hunt is a partner at RMMS. He combines substantial experience in complex litigation before federal district courts with significant involvement in the firm’s regulatory practice, where he advises clients on matters under the Federal Food, Drug, and Cosmetic Act, the Hatch-Waxman Act, the Medicare Prescription Drug, Improvement, and Modernization Act (MMA), and the Biologics Price Competition and Innovation Act (BPCIA). Most recently, Eric represented Mylan in its first ever U.S. litigation under the BPCIA, securing a favorable ruling following an earlier launch of Mylan’s FULPHILA® product, a biosimilar to the world’s leading treatment for avoidance of infection during chemotherapy
